These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18855641)

  • 21. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and evaluation a new generation of low molecular weight heparin.
    Zhao D; Sang Q; Cui H
    Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring.
    Chowdary P; Adamidou D; Riddell A; Aghighi S; Griffioen A; Priest P; Moghadam L; Kelaher N; Huq FY; Kadir RA; Tuddenham EG; Gatt A
    Br J Haematol; 2015 Mar; 168(5):719-27. PubMed ID: 25351814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Description of anti-Xa monitoring practices during low molecular weight heparin use.
    Lin A; Vazquez SR; Jones AE; Witt DM
    J Thromb Thrombolysis; 2019 Nov; 48(4):623-628. PubMed ID: 31317300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis.
    Wong SS; Lau WY; Chan PK; Wan CK; Cheng YL
    Nephrology (Carlton); 2017 Nov; 22(11):921-924. PubMed ID: 28767200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.
    Kishimoto TK; Qi YW; Long A; Capila I; Sasisekharan R; Guerrero L; Fier I; Roach J; Venkataraman G
    Thromb Haemost; 2009 Nov; 102(5):900-6. PubMed ID: 19888526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of the extrinsic pathway in the activities of low molecular weight heparins.
    Norrheim L; Abildgaard U; Larsen ML; Lindahl AK
    Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial treatment of venous thromboembolism.
    Becattini C; Agnelli G; Emmerich J; Bura A; Weitz JI
    Thromb Haemost; 2006 Sep; 96(3):242-50. PubMed ID: 16953263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosing and monitoring of low-molecular-weight heparins in special populations.
    Duplaga BA; Rivers CW; Nutescu E
    Pharmacotherapy; 2001 Feb; 21(2):218-34. PubMed ID: 11213859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group.
    Bara L; Leizorovicz A; Picolet H; Samama M
    Thromb Res; 1992 Mar; 65(4-5):641-50. PubMed ID: 1319619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
    Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
    Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of anticoagulant activity for low molecular-weight heparin by chromogenic substrate. Measurement of factor Xa and thrombin activities].
    Ishimitsu S; Sugiyama T; Itoh M; Natsuga T; Komatsu H; Okada S
    Yakugaku Zasshi; 1994 Aug; 114(8):611-7. PubMed ID: 7932105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
    Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
    Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
    Roschitz B; Beitzke A; Gamillscheg A; Sudi K; Koestenberger M; Leschnik B; Muntean W
    Thromb Res; 2003; 111(6):335-41. PubMed ID: 14698650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
    J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bemiparin: pharmacological profile.
    Sánchez-Ferrer CF
    Drugs; 2010 Dec; 70 Suppl 2():19-23. PubMed ID: 21162606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.